Medicinal composition for protecting optic nerve of glaucoma and preparation method thereof

A composition and technology for glaucoma are applied in the field of pharmaceutical compositions, pharmaceutical compositions for protecting glaucoma optic nerve and their preparation fields, and achieve the effects of determining curative effect, synergistic synergistic protection, and fast oral absorption

Inactive Publication Date: 2011-10-19
EYE & ENT HOSPITAL SHANGHAI MEDICAL SCHOOL FUDAN UNIV
View PDF1 Cites 1 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

At present, there is no combined application of VPA and adeno-associated virus vectors carrying therapeutic genes at home and abroad. It not only targets the complex pathogenesis of glaucoma, protects RGCs from multiple link

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Medicinal composition for protecting optic nerve of glaucoma and preparation method thereof
  • Medicinal composition for protecting optic nerve of glaucoma and preparation method thereof
  • Medicinal composition for protecting optic nerve of glaucoma and preparation method thereof

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0053] Example 1 The composition of sodium valproate and the adeno-associated virus vector carrying the therapeutic gene improves the expression level of the therapeutic gene in retinal cells for a long time

[0054] 1. Materials and methods

[0055] 1. Drug: sodium valproate (VPA), product of sigma company.

[0056] rAAV2-CMV-GFP (rAAV2-GFP) packaged in this laboratory

[0057] rAAV2-CMV-LUC (rAAV2-LUC) packaged and constructed in this laboratory

[0058] rAAV2-CMV--BDNF (rAAV2-BDNF) packaged and constructed in this laboratory

[0059] 2. Cells

[0060] 1) Adult retinal pigment epithelial (RPE) cells (APRE-19) are ATCC products.

[0061] 2) Adult primary RPE and IPE cells were cultured by our laboratory.

[0062] 3) Primary SD rat retinal neurons were cultured by our laboratory.

[0063] 4) Purification and culture of SD rat primary retinal ganglion cells was completed by our laboratory

[0064] 3. Animals: 40 Balb / c mice (provided by the Shanghai Experimental Animal C...

Embodiment 2

[0091] Example 2 Rescue effect of the pharmaceutical composition of sodium valproate and rAAV2-BDNF on the synergistic effect of RGCs in rats with chronic high intraocular pressure

[0092] 1. Materials and methods

[0093] 1. Drug: sodium valproate (VPA), product of sigma company.

[0094] rAAV2-BDNF, packaged and constructed by our laboratory

[0095] 2. Animals: The experimental animals were healthy SD rats (provided by the Shanghai Experimental Animal Center of the Chinese Academy of Sciences), male, 8 weeks old, weighing 180-200 g, and raised in the animal center of the hospital (12 hours of light and 12 hours of darkness).

[0096] 3. Main materials and reagents

[0097] Fluorescent gold: product of Invitrogen Company.

[0098]OX-42 monoclonal antibody and survivin monoclonal antibody were purchased from Chemicon; Bcl-2 monoclonal antibody and GFAP polyclonal antibody were purchased from Neomarker; α-synuclein and catenin monoclonal antibodies were purchased from R&D ...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The invention belongs to the field of pharmacy, and relates to a medicinal composition for protecting optic nerve of glaucoma and a preparation method thereof. The medicinal composition is prepared from 0.1 to 10 ug of sodium valproate and a therapeutic gene-carried adeno-associated virus carrier of 1*10<e9>-1*10<e12> virus particles. A compound preparation consisting of the sodium valproate and the therapeutic gene-carried adeno-associated virus carrier is prepared, or the sodium valproate and the therapeutic gene-carried adeno-associated virus carrier are respectively prepared into a medicinal preparation and the two separate medicinal preparations are packaged into the same medicine box. The medicinal composition can overcome defects of the conventional nerve protection therapy, can protect retinal ganglion cells (RGCs) through multiple links, also can drive therapeutic genes carried by the adeno-associated virus carrier to be efficiently expressed for a long time in retina cells to achieve a synergic effect on neuroprotective therapy for glaucoma, and can effectively improve the effect of the neuroprotective therapy for the glaucoma.

Description

technical field [0001] The invention belongs to the field of pharmacy and relates to a pharmaceutical composition, in particular to a pharmaceutical composition for protecting glaucoma optic nerve and a preparation method thereof. Background technique [0002] Studies have reported that glaucoma is mainly manifested as characteristic optic nerve damage and visual field defect (visual function damage), which is the first irreversible blinding eye disease in the world. Studies have found that high intraocular pressure is an important initiating factor for glaucomatous optic neuropathy. The current clinical anti-glaucoma treatment measures mainly focus on reducing intraocular pressure. With the gradual deepening of clinical and basic research on glaucoma, scholars at home and abroad have gradually formed a consensus: intraocular pressure is not the only factor in the pathogenesis of glaucoma, and simply lowering intraocular pressure can only alleviate the development of the dis...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
IPC IPC(8): A61K48/00A61P27/06A61K31/19
Inventor 孙兴怀吴继红张圣海杨伯齐武娜
Owner EYE & ENT HOSPITAL SHANGHAI MEDICAL SCHOOL FUDAN UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap